New research reveals GLP-1 drugs like Ozempic may reduce stroke risk and improve recovery. At the 22nd Annual Meeting of the ...

Why can't we sleep? Jennifer Senior, a senior staff writer at The Atlantic, talks about the stigma around sleeping pills.

This walking tour explores Shenzhen’s corporate landscape, developed for global firms and regional headquarters.

Eating disorder centers are facing an influx of people with weight-loss prescriptions. Experts say doctors are ...

GLP-1 drugs like Ozempic have already become a game-changer for obesity and diabetes. But new research shows they may also ...

A federal district court in Delaware ruled that Viatris’ product, currently awaiting approval from the US Food and Drug Administration (FDA), does not infringe on Novo Nordisk’s patent for the ...

Welcome to our live blog tracking the latest news and developments from Canada. Stay updated with real-time insights into the ...

Cash position of €7.1 million as of June 30, 2025 US$10 million milestone payment from partner Tonghua Dongbao and 2024 Research Tax Credit of €2.8 million received in July 2025 Current ...

But more big tests loom with trade talks still continuing between the Trump administration and counterparts in China and the ...

GLP-1s - which mimic the effects of the hormone that stimulates insulin release, suppressing glucagon, and slowing gastric emptying - also have a range of other benefits.

Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...